News

PharmNovo will participate in the 13th Congress of the European Pain Federation, EFIC, in Budapest from 20-22 September. The EFIC Congress is the largest international congress on pain.

PharmNovo, currently at the clinical stage of pioneering a novel solution for neuropathic pain treatment, is pleased to announce the appointment of Alexander Dahlquist as the new CFO.

PharmNovo is featured in an article in the business magazine Affärstidningen Näringsliv. Bengt von Mentzer, Founder of PharmNovo, and Per von Mentzer, CEO of PharmNovo, tell the story of our company and our vision to change the lives of people suffering from chronic neuropathic pain.

PharmNovo will participate in the LSX World Congress in London, 3-4 May. Our CEO, Per von Mentzer, will present PharmNovo and the latest progress in the ongoing clinical trial of our innovative new drug candidate for neuropathic pain, PN6047.

PharmNovo is very pleased to inform you that our former project leader, Jesper Kjerulff has returned as project leader and Chief Operations Officer.

CEO Per von Mentzer presented PharmNovo at the BioStock - Connecting Innovation and Capital Life Science Fall Summit 2022. Watch his presentation addressing the large, unmet medical needs in the neuropathic pain market and learn more about our ongoing clinical trial and how we will achieve project milestones as PharmNovo moves forward.